Malabar Institute of Medical Sciences Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2008
NCT00553631
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Alternative names

Malabar Institute of Medical Science (MIMS) | Malabar Institute of Medical Sciences Ltd. | Senior Consultant Oncologist, Malabar Institute of Medical Sciences, Calicut, India

Active Ingredients

Drugs in Phase 3 Trials (1)

imiglucerase (cerezyme) (1 trial)

Drugs in Phase 2 Trials (4)

cisplatin (platinol) (1 trial)

immuvac (1 trial)

paclitaxel (taxol) (1 trial)

riviciclib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Gaucher Disease (Phase 3)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 5